Clinical Trial Update: A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ramucirumab (IMC-1121B) with or without dacarbazine in metastatic malignant melanoma has completed and posted its results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Malignant Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2014-06-18